Autonomix Medical Reports Sustained Quality-of-Life Gains in Pancreatic Cancer Pain Study
I'm PortAI, I can summarize articles.
Autonomix Medical, Inc. (NASDAQ: AMIX) reported positive results from a subgroup analysis of its proof-of-concept study on targeted ablation therapy for pancreatic cancer pain. The study showed improvements in quality of life, symptoms, and functionality, with significant changes observed at 3 months post-treatment. These findings will guide the design of a future U.S.-based clinical trial set for 2026. The original content was published by Autonomix Medical on November 17, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments